ArticleJCEM case reports2025
Management of Graves Disease With Co-Existing Duffy-Null Phenotype.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinicians should obtain baseline white blood cell differential among those in whom antithyroid drugs (ATD) will be initiated, as patients may have neutropenia prior to initiation of ATD. We report the case of a 37-year-old male individual who had emigrated from Saudi Arabia and was found to have Graves disease. At diagnosis, the patient was leukopenic and neutropenic. Prior neutrophil counts had ranged from moderate neutropenia to normal. The patient was found to have the Duffy-null phenotype on red blood cell antigen typing, which is characterized by a clinically insignificant lower absolute neutrophil count (ANC) relative to commonly used reference ranges and no known increased risk of infection. Despite his baseline neutropenia, the patient received a standard weight-based dose of methimazole. ATD should not be withheld from patients with the Duffy-null phenotype. These patients have fewer circulating neutrophils without an increased risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.